ARRAY BIOPHARMA INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2018 12 months to Jun 30, 2018	FY2017 12 months to Jun 30, 2017	FY2016 12 months to Jun 30, 2016	FY2015 12 months to Jun 30, 2015	FY2014 12 months to Jun 30, 2014
Revenue
Reimbursement revenue
License and milestone revenue
Collaboration revenue
Collaboration and other revenue
Total revenue

Operating expenses
Cost of partnered programs
Research and development for proprietary programs
Selling, general and administrative
Total operating expenses
Gain on the Binimetinib and Encorafenib Agreements, net
Gain on sale of CMC, net
Loss from operations
Other income (expense)
Realized gain from marketable securities, net
Loss on extinguishment of Notes
Impairment loss related to cost method investment
Realized gains on investments and other
Change in fair value of notes payable
Interest income
Interest expense
Total other expense, net
Total other income (expense), net

Loss before income tax expense
Income tax expense
Net loss
Change in unrealized gain (loss) on marketable securities
Comprehensive loss
Weighted average shares outstanding – basic and diluted
Net loss per share – basic and diluted
Net loss per share – basic (in dollars per share)
Net loss per share – diluted (in dollars per share)
Weighted average shares outstanding – basic (in shares)
Weighted average shares outstanding – diluted (in shares)

Comments